Akinchan Bhardwaj: Targeting SBK2 for Selective Inflammasome Resolution in Atherosclerosis
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent article by Liangyu Cai et al, published in European Heart Journal:
“A new therapeutic target in atherosclerosis?
What if the key to treating atherosclerosis is not blocking inflammation, but resolving it?
A new study in the European Heart Journal explores something fascinating:
In advanced plaques, macrophages upregulate a kinase called SBK2.
At first glance, that looks like part of the problem. But it turns out to be part of the solution.
When SBK2 was genetically deleted, plaques worsened.
When SBK2 was overexpressed in macrophages, inflammation and plaque burden decreased.
Why?
Because SBK2 phosphorylates NLRP3, enabling its selective autophagic degradation.
In simpler terms:
The cell is not just trying to shut down inflammation.
It is trying to clear the inflammasome machinery itself.
Instead of broadly suppressing IL-1β or IL-18, this pathway promotes targeted resolution at the level of inflammasome regulation.
Even more interesting:
A small molecule (rebaudioside N) activated SBK2 and reduced plaque burden and the effect disappeared in SBK2-deficient models.
That level of target specificity is rare in preclinical inflammation research.
It reinforces a broader shift in cardiovascular biology:
Atherosclerosis is not merely lipid accumulation.
It is an immunologic microenvironment with compensatory protective circuits we barely understand.
The question for translation becomes:
Can we enhance endogenous protective pathways without impairing host defense?
If kinase-driven inflammasome resolution proves viable in humans, it may represent a new paradigm in inflammatory cardiovascular risk reduction.
The future of prevention may lie not only in lowering LDL but in precisely modulating immune balance inside the plaque. That is exciting.
Would selective inflammasome resolution be safer than systemic cytokine blockade in ASCVD?”
Title: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation
Authors: Liangyu Cai, Changhao Liu, Haonan Zheng, Qian Li, Liwen Yu, Xiaohong Wang, Yujie Zhang, Wei Yang, Ruiqing Ren, Guohai Su, Bo Li, Lei Cao, Jie Zhang, Yun Zhang, Cheng Zhang, Meng Zhang
Read the Full Article on European Heart Journal
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia